Prosecution Insights
Last updated: November 05, 2026
Application No. 16/732,872

SYSTEM AND METHODS FOR CONTROLLING ACTIVATION OF MULTIPLE APPLICATORS FOR TISSUE TREATMENT

Final Rejection §112
Filed
Jan 02, 2020
Priority
Jun 28, 2017 — provisional 62/526,214 +2 more
Examiner
AVIGAN, ADAM JOSEPH
Art Unit
3794
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cutera Inc.
OA Round
10 (Final)
44%
Grant Probability
Moderate
11-12
OA Rounds
0m
Est. Remaining
60%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
205 granted / 470 resolved
-26.4% vs TC avg
Strong +16% interview lift
Without
With
+15.9%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
21 currently pending
Career history
497
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
44.3%
+4.3% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
27.6%
-12.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 470 resolved cases

Office Action

§112
DETAILED ACTION This action is responsive to the amendment filed 9/03/26. Claims 1-8, 10-17, 20-22, 24-25 and 27 are finally rejected. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-8, 10-17, 20-22, 24-25 and 27 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 1, the claim requires: ‘… a first phase lasting a first time period, wherein at least one of the one or more energy sources sequentially provide energy to multiple non-invasive energy applicators one or more times at a first frequency of 1 MHz to 2 MHz and a first power level of 150 W to elevate temperatures of fat tissue in each target body subarea to a fat treatment temperature for a fat treatment therapy; and a second phase lasting a second time period, wherein at least one of the one or more energy sources sequentially and repeatedly provide energy to each of the plurality of noninvasive energy applicators at a second frequency different from the first frequency and at a second power level of 90 W to maintain temperatures of fat tissue in each target body subarea at the fat treatment temperature for the fat treatment therapy’ It is the examiner’s position that there is no support in the original disclosure for sequentially applying energy to the one or more applicators from the one or more energy sources at a first frequency of 1 MHz to 2 MHz and a first power level of 150 W during a temperature elevation phase and sequentially and repeatedly applying energy to the one or more applicators from the one or more energy sources at a second frequency different than the first frequency and at a second power level of 90 W during a temperature maintenance phase, as required by the claim. Applicant’s ‘Remarks’ cite par. 54 for the disclosure of the ‘first power level of 150 W’ during the temperature elevation phase. Par. 54 states: As shown in FIG. 5A, applicator “1” is initially provided with a warm up power level (e.g., 150 W) for a predetermined period of time.” Therefore, the examiner agrees that par. 54 provides support for the specific power level of 150 W during the temperature elevation phase, however, the examiner notes that par. 54 is silent about the ‘first frequency of 1 MHz to 2 MHz’ aspect. To remedy this, applicant cites par. 46 to provide support for the ‘first frequency of ‘1 MHz to 2 MHz’ aspect. Par. 46 states: For example, at least in the frequency range 200 kHz to 10 MHz, fat may reach a higher temperature than skin when experiencing the same applied energy source due to differences in RF attenuation coefficients and thermal properties of fat and skin. While operation within this range provides favorable treatment conditions more favorable treatment outcomes may result by further limiting the frequency range, depending on goal of the treatment. For example, increasing the frequency from 1 MHz to 2 MHz increases the temperature differential between fat and skin by 3° C. for typical treatment conditions. While the examiner agrees that this passage provides general support for the use of a frequency within the range of 1 MHz to 2 MHz and even teaches that this frequency range increases the temperature differential between fat and skin tissue by 3° C, the examiner disagrees that par. 46 provides adequate support for the selection of a frequency within this range used in conjunction with a power level 150 W to ‘elevate temperatures of fat tissue in each target body subarea to a fat treatment temperature for a fat treatment therapy’. Therefore, while the original disclosure supports the use of a ‘warm-up power level’ of 150 W in par. 54 and separately a frequency range of ‘1 MHz to 2 MHz’ in par. 46, there is no direct teaching of using these energy parameters together to ‘elevate temperatures of fat tissue’ during a temperature warm-up phase. In addition, while par. 55 discloses the use of a ‘nominal power level (e.g., 90 W) to maintain the tissue at the target temperature,’ par. 55 is silent on the selection of ‘a second frequency different from the first frequency’ delivered in conjunction with the 90 W power level ‘to maintain temperatures of fat tissue’. Further, while par. 46 (cited by applicant’s “Remarks”) generally teaches that ‘frequency affects the heating rate when the energy is applied to various tissues as well as the temperature differential between different tissues, such as skin and fat’, this teaching alone does not adequately demonstrate that applicant had possession of selecting a ‘second frequency different from the first frequency and at a second range of power level of 90 W to maintain temperatures of fat tissue.’ At best applicant has demonstrated that applicant recognized frequency as a result-effective variable which affects heating rates of tissue and temperature differentials between tissues, however, this does not prove that applicant had possession of applying different frequencies during the temperature elevation and temperature maintenance phases, respectively. Therefore, claim 1 contains new matter. Claim 20 is rejected for substantially similar reasons to those discussed with respect to claim 1, above. Response to Arguments Applicant's arguments, see “Remarks”, filed 9/3/26 have been fully considered but they are not persuasive. The arguments have already been addressed in the body of the rejection. Therefore, the response will not be reiterated. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ADAM JOSEPH AVIGAN whose telephone number is (571)270-3953. The examiner can normally be reached Monday-Friday 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Stoklosa can be reached at (571) 272-1213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ADAM JOSEPH. AVIGAN Examiner Art Unit 3739 /ADAM J AVIGAN/Examiner, Art Unit 3794 /JOSEPH A STOKLOSA/Supervisory Patent Examiner, Art Unit 3794
Read full office action

Prosecution Timeline

Show 21 earlier events
Mar 20, 2025
Response Filed
May 21, 2025
Final Rejection mailed — §112
Jul 18, 2025
Response after Non-Final Action
Sep 22, 2025
Request for Continued Examination
Oct 02, 2025
Response after Non-Final Action
May 06, 2026
Non-Final Rejection mailed — §112
Sep 03, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766241
IRRIGATED CATHETER SYSTEM INCLUDING FLUID DEGASSING APPARATUS AND METHODS OF USING SAME
4y 9m to grant Granted Oct 20, 2026
Patent 12728033
THERMAL COMPRESSIVE SURGICAL TREATMENT MASK
1y 5m to grant Granted Sep 08, 2026
Patent 12714595
METHODS AND APPARATUSES FOR MANIPULATING TEMPERATURE
8y 11m to grant Granted Aug 25, 2026
Patent 12708440
COMPACT DELIVERY PULMONARY TREATMENT SYSTEMS AND METHODS FOR IMPROVING PULMONARY FUNCTION
7y 6m to grant Granted Aug 18, 2026
Patent 12702585
COOLING CAP ASSEMBLY AND COOLING UNIT
2y 7m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

11-12
Expected OA Rounds
44%
Grant Probability
60%
With Interview (+15.9%)
4y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 470 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month